A biocompatible soft tissue implant for introduction into a human body includes at least one layer comprising an elastomeric material, and at least one textile fabric arranged on the at least one layer comprising the elastomeric material. The at least one textile fabric forms a surface of the biocompatible soft tissue implant. The at least one textile fabric includes bioresorbable fibers which are embedded at least partially in the at least one layer comprising the elastomeric material.

A biocompatible composite material for complete or partial insertion into a human body includes at least one layer comprising an elastomeric material, and at least one textile fabric arranged on the at least one layer comprising the elastomeric material. The at least one textile fabric forms a surface of the biocompatible composite material. The at least one textile fabric includes bioresorbable fibers that are embedded at least partially in the at least one layer comprising the elastomeric material.

An angioplasty device may comprise a catheter, a balloon disposed on the catheter, and a scaffold disposed over the balloon. The scaffold may comprise an electrospun polymer fiber and an agent dispersed within the fiber. A method of making such an angioplasty device may comprise obtaining a catheter having a balloon disposed on it, contracting the balloon, and electrospinning a polymer solution onto the surface of the catheter having the balloon, thereby forming a scaffold disposed over the balloon. The polymer solution may comprise a polymer, a solvent, and an agent. A method of performing an angioplasty procedure may comprise inserting such an angioplasty device into a blood vessel, placing the angioplasty device near a lesion within the blood vessel, expanding the balloon, thereby contacting the lesion with the scaffold, contracting the balloon, and removing the angioplasty device from the blood vessel.

In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.

The present invention disclosed a process to coat the surface of flexible polymeric implant with biocompatible polymer such that the coating does not crack when the implant is subjected to mechanical forces such as tension, torsion or bending while retaining the inherent properties of the coated polymer.

Generally, the invention is in relation to the field of drug delivery devices to augment standard radiation therapy and methods of making and using same. Specifically, this technology utilizes a controlled release of drug from a coated balloon for local intratumoral drug delivery to breast tissue to supplement or replace standard radiation therapy.

Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

Generally, the invention is in relation to the field of drug releasing insertable devices and methods of making and using same. Specifically, this technology relates to controlled release of drug from a coated balloon directly into affected tissue regions within the body of an individual.